

Claims:

5 1. A method for the preparation of *trans*- or *cis*-
diammoniumdichlorodihydroxoplatinum(IV) or derivatives
thereof,
characterized in that
trans- or *cis*-diammoniumdichloroplatinum(II) is reacted
10 with a solution comprising >30% peroxide at tempera-
tures below 30°C, and the product thus obtained is dis-
solved in a mineral acid and subsequently precipitated
with an alkaline solution.

15 2. A compound of general formula



25 wherein X_1, X_2 = calcium, magnesium, sodium, potassium,
lithium ions, alkyl and/or aryl residues.

30 3. Use of the compound according to claim 2 in prophylaxis,
therapy, follow-up and aftercare of diseases associated with cell growth,
cell differentiation and/or cell division.

35 4. The use according to the preceding claim,
characterized in that
the disease is a tumor.

5. The use according to the preceding claim,
characterized in that
the compound is employed orally, vaginally, rectally,
nasally, subcutaneously, intravenously, intramuscu-
larly, intraperitoneally, regionally and/or topically.
6. A pharmaceutical agent, comprising a compound according
to claim 2, optionally together with a pharmaceutically
tolerable carrier, adjuvant and/or vehicle.
7. The pharmaceutical agent according to the preceding
claim,
characterized in that
the carriers are selected from the group comprising
fillers, diluents, binders, humectants, disintegrants,
dissolution retarders, absorption enhancers, wetting
agents, adsorbents and/or lubricants.
8. The pharmaceutical agent according to any of the pre-
ceding claims,
characterized in that
the carriers are liposomes, siosomes and/or niosomes.
9. A kit, comprising the compounds according to claim 2,
optionally together with information for combining the
contents of the kit.
10. Use of the kit according to the preceding claim in the
prophylaxis or therapy of tumor diseases.